# An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

> **NCT04620811** · PHASE3 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 159 (actual)

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Duodenitis

## Interventions

- **DRUG:** lirentelimab

## Key facts

- **NCT ID:** NCT04620811
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-03
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-07-07
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620811, "An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04620811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*